Forward Looking Statements

Some of the information presented here today may contain projections or other forward-looking statements regarding future events or the future financial performance of the Company. These statements are based on management’s current expectations and the actual events or results may differ materially and adversely from these expectations. We refer you to the documents the Company files from time to time with the Securities and Exchange Commission, specifically, the Company’s annual reports on Form 10-K, its quarterly reports on Form 10-Q, and its current reports on Form 8-K. These documents identify important risk factors that could cause the actual results to differ materially from those contained in the Company’s projections or forward-looking statements.
Our vision...

A trusted advisor transforming patients’ lives worldwide with pioneering molecular diagnostics

The Global Leader in Personalized Medicine
Myriad's 4 in 6 Mission Statement

Answering patients’ four most pressing questions

Will I get a disease?
Do I have a disease?
Should I treat this disease?
How should I treat this disease?

In six medical specialties

- Oncology
- Preventive Care
- Urology
- Dermatology
- Autoimmune
- Neuroscience
Unmatched Competitive Advantages in Personalized Medicine

- Profitable R&D driven molecular diagnostic company
- Expertise in DNA, RNA, and proteins
- Strong research capabilities; extensive collaborations (>50 institutions and >20 pharma/bio companies)
- Broad regulatory experience (CLIA, FDA, CE mark)
- Deep physician relationships (>90,000 ordering physicians since inception)
- Extensive managed care contracts (>600)
- Reputation for best-in-class quality for high-complexity tests (>2 million performed)
Our Strategic Goals By 2020

- Revenue Growth CAGR >10%
- Operating Margin >30%
- 7 Products with Revenue >$50 Million
- International Revenue >10%

Goals by 2020
Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals

- Transition & Expand the Hereditary Cancer Market
- Diversify the Portfolio
- Increase International Contribution
Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals

- Transition & Expand the Hereditary Cancer Market
- Diversify the Portfolio
- Increase International Contribution
Hereditary Cancer Revenue Has Been More Durable Than Investors Anticipated

- Medicare price reduction
- Higher Medicaid mix
- Small private payer reductions

Share loss concentrated in the academic/genetic segment

Market Share
- Q2 FY16: 90%
- Q4 FY13: 94%

ASP
- Q2 FY16: 94%
- Q4 FY13: 94%
### Sustainable Competitive Advantages Expand in the Future

<table>
<thead>
<tr>
<th>Factor</th>
<th>Lab Accuracy</th>
<th>Variant Classification</th>
<th>Customer Support</th>
</tr>
</thead>
</table>
| **Myriad Advantages** | • Requires perfection  
• 85,000 bases analyzed  
• 856 distinct manufacturing steps  
• 23 major technology platforms  
• 100 proprietary software applications | • 20 years of research and >$100M investment  
• 2 million patients tested  
• 40,000 variant database that is rapidly expanding  
• Avoid public databases that are fraught with errors  
• Proprietary methods | • 11,000 oncologists and breast surgeons  
• 35,000 OBGYNs  
• 375 person sales team  
• 80 person clinical team  
• Tailored report developed with >40,000 coding hours  
• Extensive managed care contracts (>600)  
• Industry leading turnaround time |
Our Strategic Imperatives to Achieve Our FIVE-Year Goals

Transition & Expand the Hereditary Cancer Market

Diversify the Portfolio

Increase International Contribution
Industry Leading Pipeline Facilitates Long-Term Growth

Total Addressable Market (TAM)

<table>
<thead>
<tr>
<th>Stage 3 REIMBURSEMENT</th>
<th>Stage 2 VALIDATION</th>
<th>Stage 1 DISCOVERY</th>
</tr>
</thead>
<tbody>
<tr>
<td>• myRisk Hereditary Cancer</td>
<td>• myPath® Melanoma</td>
<td>• myPath® Bipolar</td>
</tr>
<tr>
<td>• Vectra DA®</td>
<td>• myChoice™ HRD (Platinum)²</td>
<td>• myPath® Pancreatic Cancer</td>
</tr>
<tr>
<td>• Prolaris®</td>
<td>• myChoice HRD™ (PARP)³</td>
<td>• myPath® Psoriatic Arthritis</td>
</tr>
<tr>
<td>• EndoPredict®</td>
<td>• myPlan® Lung Cancer</td>
<td>• myPath® Prostate Cancer</td>
</tr>
<tr>
<td>• BRACAnalysis CDx™¹</td>
<td>• myPlan® Renal Cancer</td>
<td>• myPath® Endometriosis</td>
</tr>
<tr>
<td>• Tumor BRACAnalysis CDx®</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

¹ Ovarian Cancer, Breast Cancer, Pancreatic Cancer
² Triple Negative Breast Cancer, HER2- Breast Cancer
³ Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Metastatic Prostate Cancer
Vectra DA Fills a Substantial Unmet Clinical Need in Rheumatology Market

- Historical methodology for assessing rheumatoid arthritis disease activity has been subjective physician joint assessment (DAS 28)
- Unable to detect changes in disease activity before irreversible bone damage
- Vectra DA is a 12 protein biomarker test that provides an objective assessment of disease activity
- Multiple studies show the test’s ability to predict radiographic progression (gold standard endpoint for RA)
- Current volume run rate 170k tests per year
- 1.5 million patients in U.S. with RA
- $3B global market opportunity
Prolaris Fills Significant Unmet Need in Urology Market

- Helps prostate cancer patients choose between therapy and active surveillance
- 10 clinical studies with >4,000 patients
- Indicated for 500,000 global patients per year with a TAM of $1.5B
- Medicare reimbursement currently supports $200M U.S. market
- Signed private contracts representing 28M covered lives
- ≈30% of urologists have ordered the test

*Cuzick 2015 AUA
Complete Suite of Companion Diagnostic Solutions

<table>
<thead>
<tr>
<th>Sample</th>
<th>BRACAnalysis CDx</th>
<th>Tumor Panel</th>
<th>Immune Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood</td>
<td>Blood</td>
<td>Tumor</td>
<td>Tumor</td>
</tr>
<tr>
<td>Tumor</td>
<td>Tumor</td>
<td>Tumor</td>
<td>Tumor</td>
</tr>
<tr>
<td>Tumor</td>
<td>Tumor</td>
<td>Tumor</td>
<td>Tumor</td>
</tr>
<tr>
<td>Tumor</td>
<td>Tumor</td>
<td>Tumor</td>
<td>Tumor</td>
</tr>
<tr>
<td>Sample</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Biomarkers</td>
<td>BRCA1&amp;2</td>
<td>Genome-wide assessment of DNA scar associated with DNA repair defects</td>
<td>80+ clinically actionable oncology genes identified by pharma partners</td>
</tr>
<tr>
<td>Database, process, bioinformatics</td>
<td>Database, process, bioinformatics</td>
<td>MYGN has IP on three proprietary technologies (LOH, TAI, LST)</td>
<td>Database, process, bioinformatics</td>
</tr>
<tr>
<td>Currently Marketed</td>
<td>FDA approved</td>
<td>Early access launch for platinum</td>
<td>In research use with major pharma partners</td>
</tr>
</tbody>
</table>

myPath Melanoma Beginning Reimbursement Process

- 5 clinical studies with \( \approx 2,000 \) patients
- Indicated for 400,000 global patients per year with a TAM of \$600M
- 24% of dermatopathologists in the U.S. have ordered the test
- 138% volume growth in FY15

---

**myPath Melanoma Diagnostic Accuracy**

<table>
<thead>
<tr>
<th>Validation</th>
<th>n (patients)</th>
<th>Diagnostic Accuracy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Validation 1</td>
<td>437</td>
<td>90%</td>
</tr>
<tr>
<td>Validation 2</td>
<td>736</td>
<td>92%</td>
</tr>
</tbody>
</table>

Favorable outcomes study to be presented.
Our Strategic Imperatives to Achieve Our **FIVE**-Year Goals

- Transition & Expand the Hereditary Cancer Market
- Diversify the Portfolio
- Increase International Contribution
## Refined Strategy to Reflect Unique International Market

<table>
<thead>
<tr>
<th>COUNTRIES</th>
<th>REFERENCE TESTS</th>
<th>KITS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Near-Term Growth:</strong></td>
<td><strong>DNA (multiple platforms):</strong> myRisk</td>
<td>RNA (platform partner):</td>
</tr>
<tr>
<td>EU6 + Canada</td>
<td>Companion Diagnostics</td>
<td>• EndoPredict</td>
</tr>
<tr>
<td><strong>Long-Term Growth:</strong></td>
<td></td>
<td>• Prolaris</td>
</tr>
<tr>
<td>Japan, China, and Brazil</td>
<td></td>
<td>• myPlan Lung</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPath Melanoma</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPlan Renal</td>
</tr>
<tr>
<td></td>
<td></td>
<td><strong>Protein (platform partner):</strong></td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Vectra DA</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPath Bipolar</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• myPath Pancreatic</td>
</tr>
</tbody>
</table>
Goal to Get to 10% of Revenue From International Markets by FY20

Goal to have international product revenue comprise 10% of sales by FY20
Financial Outlook
Five Year Plan Anticipates Greater Than 10% Revenue CAGR Over Next Five Years

- HEREDITARY CANCER
- COMPANION DX
- VECTRA DA
- PROLARIS
- MYPATH MELANOMA
- PHARMA & CLIN SERVICES/OTHER

Less than 50% of revenue from hereditary cancer

Market Penetration 9%
Increased Profitability In Pipeline Products
Supports >30% Operating Margins

OPERATING LEVERAGE

<table>
<thead>
<tr>
<th>Year</th>
<th>Hereditary Cancer</th>
<th>Autoimmune</th>
<th>Urology</th>
<th>Dermatology</th>
<th>International</th>
<th>FY20</th>
</tr>
</thead>
<tbody>
<tr>
<td>FY15</td>
<td>(6.0%)</td>
<td>7.0%</td>
<td>3.0%</td>
<td>1.0%</td>
<td>2.0%</td>
<td>35%</td>
</tr>
</tbody>
</table>
# Capital Deployment Strategy

<table>
<thead>
<tr>
<th>Capital Allocation Priority</th>
<th>Capital Deployment Since June 2010</th>
<th>Goal</th>
</tr>
</thead>
<tbody>
<tr>
<td>R&amp;D</td>
<td>9% of revenue</td>
<td>8% to 10% of revenue</td>
</tr>
</tbody>
</table>
| M&A                        | ≈ $340M                           | - Use cash on hand to fund smaller deals (< $100M)  
                                |                                  | - Use cash and leverage to fund larger deals ($100M-$600M)  
                                |                                  | - Use equity to fund strategic deals (beyond borrowing capacity) |
| Share Repurchase           | >$1B                              | - Target 100% of FCF  
                                |                                  | - Reduce share repurchases based upon M&A visibility  
                                |                                  | - Maintain cash at $100M to $200M |
| Dividend                   | None                              | No plans for dividend given more attractive uses of capital |
Worldwide Leader in Personalized Medicine

• We are entering the golden age for personalized medicine
• We are the pioneers of “research-based” and “education-centric” business modeling for diagnostics
• No company is better positioned to lead this revolution in healthcare than Myriad